rDEN2Δ30-7169

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

rDEN2Δ30-7169 is one of 3 biologic programs targeting Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DengueNot yet recruiting

DenguePhase 1

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Dengue

#DrugCompanyPhaseTrials

Biological

NNational Environment Agency, Singapore

Preclinical

2 2

rDEN2Δ30-7169

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 3

Emetine Hydrochloride

JJohns Hopkins University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Infection

NCT06908018

Clinical

Trials by Indication[1]

2 more indications

Infection1 trial

Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)

Not yet recruiting·MMahidol University·Phase 1·NCT06908018·12 enrolled

Dengue1 trial

Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.

Not yet recruiting·MMahidol University·Phase 1·NCT05476757·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for rDEN2Δ30-7169. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rDEN2Δ30-7169 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rDEN2Δ30-7169. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

rDEN2Δ30-7169

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Immune Response2 trials

Single Dose1 trial

Safety and Efficacy1 trial

Effectiveness1 trial

Efficacy1 trial

Infection1 trial

Dengue1 trial

References

Drug Info

Quick Facts

Related News